期刊文献+

Graves眼病3种药物治疗方案的成本-效果分析 被引量:1

3 Therapeutical Schemes on Graves Ophthalmopathy:Cost-effectiveness Analysis
下载PDF
导出
摘要 目的研究Graves眼病(GO)3种药物治疗方案的成本-效果。方法94例GO患者分为3组,分别给予甲基强的松龙(A组)、地塞米松(B组)和强的松(C组),用成本-效果分析法进行评价。结果A、B、C组成本分别为2956.76元、2059.42元、31.09元;总有效率分别为93.94%、93.75%、51.72%;成本-效果比分别为31.47元、21.97元、0.60元;A、B组相对于C组的增量成本-效果比分别为69.30元、48.26元。结论从药物经济学角度分析,B方案治疗GO相对较好。 OBJECTIVE: To Study the cost- effectiveness among 3 therapeutical schemes in the treatment of Graves ophthalmopathy. METHODS: A total of 94 cases with Graves ophthalmopathy were randomized into 3 groups, Group A was assigned to receive medrat,Group B to receive dexamethasone and Group C to receive prednisone,the outcomes were evaluated in terms of the cost- effectiveness analysis. RESULTS: The costs for Group A, B and C were 2 956.76 yuan, 2 059.42 yuan and al. 09 yuan, respectively. The total effective rates were 9a. 94%, 9a. 75% and 51.72%, respectively. The cost - effectiveness ratios were 31.47 yuan, 21.97 yuan and 0.60 yuan, respectively. The incremental cost- effectiveness ratios of Group A and B were 69.30 yuan and 48.26 yuan, respectively as against Group C. CONCLUSION: In terms of pharmacoeconomies, Group B is comparatively the best option in treating Graves ophthalmopathy.
作者 奚月芬 高芸
出处 《中国药房》 CAS CSCD 北大核心 2006年第1期34-35,共2页 China Pharmacy
关键词 GRAVES眼病 治疗方案 成本-效果分析 Graves ophthalmopathy Therapeutical schemes Cost - effectiveness analysis
  • 相关文献

参考文献4

二级参考文献6

共引文献206

同被引文献20

  • 1Maheshwari R, Weis E. Thyroid associated orbitopathy[J]. lndian J Ophthalmol, 2012,60 ( 2 ) : 87.
  • 2Park JJ, Sullivan T J, Mortimer RH, et al. Assessing qual- ity of life in Australian patients with Graves' ophthalmop- athy[J]. Br J Ophthalmol, 2004,88 ( 1 ) : 75.
  • 3Farid M, Roch-Levecq AC, Levi L, et al. Psychological disturbance in graves ophthalmopathy[J]. Arch Ophthal- mol,2005,123(4) :491.
  • 4Terwee CB, Gerding MN, Dekker FW, et al. Develop- ment of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: The GO-QOL[J]. BrJ Ophthalmol, 1998,82(7) : 773.
  • 5Terwee CB, Gerding MN, Derkker FW, et al.Test-retest re- liability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy [J]. J Clin Epidemiol, 1999,52 (9) : 875.
  • 6Terwee CB, Dekker FW, Mourits MP, et al. Interpreta- tion and validity of changes in scores on the Graves' oph- thalmopathy quality of life questionnaire (GO-QOL)after different treatment [J]. Clin Endocrinol: Oxf, 2001, 54 (3):391.
  • 7Pointdujour R, Gutman J, Shinder R. Quality of life in a German graves orbitopathy population[J]. Am J Ophthal- mol, 2012,153(2) : 380.
  • 8Yeatts RP. Quality of life in patients with Graves' ophthal-mopathy[J]. Trans Am Ophthalmol Soc, 2005 ( 103 ) : 368.
  • 9Lee H, Roh HS, Yoon JS, et al. Assessment of quality of life and depression in Korean patients with Graves' oph- thalmopathy [J]. Korean J Ophthalmol , 201 0, 24 (2) : 65.
  • 10Gerding MN, Terwee CB, Dekker FW, et al. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument[J]. Thyroid, 1997,7(6) : 885.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部